Analysts Set Capricor Therapeutics Inc (NASDAQ:CAPR) Target Price at $19.80

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given an average rating of “Buy” by the five ratings firms that are covering the firm, MarketBeat Ratings reports. Five analysts have rated the stock with a buy recommendation. The average 1-year price target among analysts that have covered the stock in the last year is $20.00.

Several analysts recently commented on the stock. Oppenheimer raised their price objective on shares of Capricor Therapeutics from $14.00 to $15.00 and gave the company an “outperform” rating in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of Capricor Therapeutics in a research report on Tuesday.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAPR. BNP Paribas Financial Markets acquired a new stake in Capricor Therapeutics in the 1st quarter worth about $40,000. Main Street Financial Solutions LLC boosted its position in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. Rhumbline Advisers acquired a new position in Capricor Therapeutics during the second quarter worth approximately $147,000. Jump Financial LLC purchased a new position in Capricor Therapeutics during the fourth quarter worth approximately $258,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after purchasing an additional 9,040 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock opened at $4.99 on Tuesday. The business has a 50 day simple moving average of $4.36 and a 200-day simple moving average of $5.18. Capricor Therapeutics has a 12 month low of $2.68 and a 12 month high of $7.28. The stock has a market capitalization of $159.58 million, a PE ratio of -5.74 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The business had revenue of $3.97 million for the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. As a group, equities research analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current year.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.